TY - JOUR
T1 - Biomarkers of neurological disease
AU - Okamura, Nobuyuki
AU - Yanai, Kazuhiko
AU - Furukawa, Katsutoshi
AU - Arai, Hiroyuki
AU - Kudo, Yukitsuka
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/5
Y1 - 2010/5
N2 - Biomarkers play an important role in the study of neurological disease. In neurodegenerative disease, the pathophysiologic process leading to neuron death begins before clinical symptoms develop. Therefore, one of the most important roles of biomarkers is an accurate diagnosis of diseases in their early and presymptomatic stages. Another important role of biomarkers is to serve as potential surrogate markers of disease severity. Biomarkers can also be used to improve safety assessment and determine appropriate dosage of the drug. Various biomarkers have been developed for clinical assessment of Alzheimer's disease. Tau and amyloid-β protein in cerebrospinal fluid are useful biomarkers for early diagnosis of Alzheimer's disease. Recent development of molecular imaging probes enables noninvasive detection of amyloid plaques using positron emission tomography (PET). PET amyloid imaging may be useful for early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials, and monitoring of the effect of anti-amyloid therapy. A multisite, prospective clinical study was launched to develop standardized neuroimaging and biomarker methods for clinical trial on Alzheimer's disease.
AB - Biomarkers play an important role in the study of neurological disease. In neurodegenerative disease, the pathophysiologic process leading to neuron death begins before clinical symptoms develop. Therefore, one of the most important roles of biomarkers is an accurate diagnosis of diseases in their early and presymptomatic stages. Another important role of biomarkers is to serve as potential surrogate markers of disease severity. Biomarkers can also be used to improve safety assessment and determine appropriate dosage of the drug. Various biomarkers have been developed for clinical assessment of Alzheimer's disease. Tau and amyloid-β protein in cerebrospinal fluid are useful biomarkers for early diagnosis of Alzheimer's disease. Recent development of molecular imaging probes enables noninvasive detection of amyloid plaques using positron emission tomography (PET). PET amyloid imaging may be useful for early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials, and monitoring of the effect of anti-amyloid therapy. A multisite, prospective clinical study was launched to develop standardized neuroimaging and biomarker methods for clinical trial on Alzheimer's disease.
KW - Alzheimer's disease
KW - Biomarker
KW - Cerebrospinal fluid
KW - Early diagnosis
KW - Positron emission tomography (PET)
UR - http://www.scopus.com/inward/record.url?scp=77953731134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953731134&partnerID=8YFLogxK
U2 - 10.3999/jscpt.41.101
DO - 10.3999/jscpt.41.101
M3 - Article
AN - SCOPUS:77953731134
VL - 41
SP - 101
EP - 106
JO - Japanese Journal of Clinical Pharmacology and Therapeutics
JF - Japanese Journal of Clinical Pharmacology and Therapeutics
SN - 0388-1601
IS - 3
ER -